» Articles » PMID: 22633469

Impact of 3D Image-based PDR Brachytherapy on Outcome of Patients Treated for Cervix Carcinoma in France: Results of the French STIC Prospective Study

Overview
Journal Radiother Oncol
Specialties Oncology
Radiology
Date 2012 May 29
PMID 22633469
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: In 2005 a French multicentric non randomized prospective study was initiated to compare two groups of patients treated for cervix carcinoma according to brachytherapy (BT) method: 2D vs 3D dosimetry. The BT dosimetric planning method was chosen for each patient in each center according to the availability of the technique. This study describes the results for 705 out of 801 patients available for analysis.

Patients And Methods: The DVH parameters for CTVs (High Risk CTV and Intermediate Risk CTV) and organs at risk (OARs) were computed as recommended by GYN GEC ESTRO guidelines. Total doses were converted to equivalent doses in 2Gy fractions (EQD2). Side effects were prospectively assessed using the CTCAEv3.0.

Results: At 24 months, local relapse-free survival was 91.9% and 100% in group 1, 84.7% and 93% in group 2, 73.9% and 78.5% in group 3; grade 3-4 toxicity rate was 14.6% and 8.9% in group 1, 12.5% and 8.8% in group 2, and 22.7% and 2.6% in group 3 for 2D and 3D arm.

Conclusion: This multicentric study has shown that 3D BT is feasible and safe in routine practice. It has improved local control with half the toxicity observed with 2D dosimetry. The combined treatment with radiotherapy and surgery was more toxic than definitive radiotherapy. For patients with advanced tumors, it is necessary to improve coverage of target volumes without raising toxicity.

Citing Articles

Now or Later? The Role of Neoadjuvant Treatment in Advanced Endometrial Cancer: A Systematic Review.

Ronsini C, Iavarone I, Carotenuto A, Raffone A, Andreoli G, Napolitano S Healthcare (Basel). 2024; 12(23).

PMID: 39685026 PMC: 11641141. DOI: 10.3390/healthcare12232404.


Low-dose-rate, high-dose-rate, and pulsed-dose-rate intra-cavitary brachytherapy for cervical cancer: The very first comparison study.

Sharma D, Kumar P, Subramani V, Giridhar P J Contemp Brachytherapy. 2024; 16(4):273-278.

PMID: 39628820 PMC: 11609853. DOI: 10.5114/jcb.2024.142938.


External beam radiotherapy followed by image-guided adaptive brachytherapy in locally advanced cervical cancer: a multicenter retrospective analysis.

Cena S, Olivero F, Martini S, Gianello L, Boriano A, Merlotti A Radiol Med. 2024; 129(12):1906-1915.

PMID: 39448439 DOI: 10.1007/s11547-024-01899-4.


Dose escalation with stereotactic body radiotherapy for cervical cancer treatment.

Turna M, Rzazade R, Kucukmorkoc E, Kucuk N, Canoglu M, Caglar H BMC Cancer. 2024; 24(1):1281.

PMID: 39407149 PMC: 11481774. DOI: 10.1186/s12885-024-13017-8.


Comparative Analysis of External and Internal Radiotherapy- Dependent Plans in Patients with Gynecological Cancer.

Vourtsas P, Sarris K, Giakoumakis N, Kolitsi G, Kyprianou K, Mastronikoli S Cancer Diagn Progn. 2024; 4(3):352-358.

PMID: 38707738 PMC: 11062162. DOI: 10.21873/cdp.10331.